Search

These data consolidate the Barcelona Science Park as one of the most powerful hubs for public innovation in health in Europe and reaffirm its role as a key player in the advancement of socio-economic

Agarose Bead Technologies has enhanced its Burgos facility by boosting its agarose resin production to 100,000 liters annually to position itself as a powerhouse in the novel therapies market.

Spanish company Quibim's QP-Prostate solution, which uses biopsy and MRI data for training, achieves higher accuracy than traditional methods.

ATX-01 is the industry’s first anti-microRNA therapeutic to be investigated in DM1

For the treatment of aggression and social withdrawal.

Peaches starts its phase I-II pilot trial to obtain an advanced biologic drug that will help combat cytokine storm, a very common reaction in patients with COVID-19, but also in other pathologies such

David Segarra, an aptamer technology entrepreneur, co-founded aptaTargets in 2014 and has led the company to bring ApTOLL to the clinic. Previously, he was co-founder and CEO of Aptus Biotech, an

This funding will allow the company -based in the Barcelona Science Parkspeed up the path to market of their first product, HyperSperm, a revolutionary technique that seeks to increase the

Peaches starts its phase I-II pilot trial to obtain an advanced biologic drug that will help combat cytokine storm, a very common reaction in patients with COVID-19, but also in other pathologies such

The international study involves the Complexo Hospitalario Universitario de A Coruña in Spain and two other sites in Italy.

The OLEAF4VALUE project is an ambitious initiative funded by the European Union under the Horizon 2020 program, aimed at transforming olive leaf biomass, an underutilized resource, into high-value

Despite market contraction in 2023, strategic interest in biologics and advanced therapies remains robust, with a rebound expected by 2025.

Oryzon may use STAXI-2 Trait anger as a primary efficacy endpoint for PORTICO-2.

Similar to Sabadell Asabys Fund I, the Fund II portfolio will include companies within the fields of biopharma, medtech and digital health that provide a clear benefit for patients.

We interviewed Pedro Martínez Córdoba, Councilman for Economic Promotion at the Salamanca City Council, Silver Sponsor of the fifth edition of the Green Innovation Forum.

Simbionte has been selected to join Lanzadera, one of the leading acceleration programs in Europe. This opportunity will allow the agency to solidify its position as the top choice for Biotech SMEs